Skip to main content

Advertisement

SpringerLink
Log in

Anxiety in Elderly Patients

A Comparison of Azapirones and Benzodiazepines

  • Drug Therapy
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

The onset of primary generalised anxiety or other anxiety disorders during old age is unusual. However, these disorders are often chronic and may persist into old age, so that their occurrence in the elderly population is not rare. Secondary anxiety is also very common and may be related to endogenous stimuli, such as concomitant medical illness, or exogenous events such as loss of friends, change in life status or financial concerns.

As the elderly constitute the most rapidly growing segment of the population of many developed nations, this is a problem of significant proportion. Anxiety disorders cause considerable morbidity and dysfunction and have even been shown to increase mortality rates.

Nonetheless, the disorders are readily diagnosable if symptoms are properly interpreted. Failure to do so, dramatically and unnecessarily inflates healthcare costs. Certain presentations are more typical in the elderly. For example, somatisation and generalised anxiety are more common, and panic disorder is seen less often, in elderly than in younger patients.

Once diagnosed, both nondrug and drug interventions may be effective. Benzodiazepines, although well recognised as useful, have been excessively criticised in terms of general use in the past. Extreme caution is warranted when these agents are used in geriatric patients as they may exacerbate cognitive impairment and cause psychomotor effects that may lead to adverse events and outcomes.

Newer agents, such as the azapirones, have a lag-time to onset of action and require patient education for efficient use. They are, however, very effective in elderly patients and have been shown to be remarkably free of dangerous adverse effects. They have a very favourable risk to benefit profile in the elderly.

Proper selection of therapeutic intervention allows clinicians to relieve symptoms with minimal risk of adverse effects in elderly patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cadieux RJ. Geriatric psychopharmacology. Postgrad Med 1993; 93(4): 281–301

    PubMed  CAS  Google Scholar 

  2. Jenike MA. Geriatric psychiatry and psychopharmacology: a clinical approach. St Louis: Mosby Year Book, 1989: 1–6

    Google Scholar 

  3. Stahl SM, Boschert S. Anxiety may underlie chest pain, dyspnea in elderly. Intern Med News Cardiol News 1994 March 15: 30

    Google Scholar 

  4. Wilcox SM, Himmelstein DU, Woolhandler S. Inappropriate drug prescribing in the community-dwelling elderly. JAMA 1994; 272: 292–6

    Google Scholar 

  5. Baughman III OL. Diagnosis and management of anxiety in the older patient: the role of azapirones. Adv Ther 1989; 6(6): 269–86

    Google Scholar 

  6. Green M, Sussman N. The treatment of anxiety in elderly patients. Top Psychiatry Prim Care Physician 1989; 1(1): 4

    Google Scholar 

  7. Cohen GD. Prevalence of psychiatric problems in older adults. Psychiatr Ann 1990; 20(8): 433–8

    Google Scholar 

  8. German PA, Shapiro S, Skinner EA. Mental health of the elderly: use of health and mental health services. J Am Geriatr Soc 1985; 33: 246–52

    PubMed  CAS  Google Scholar 

  9. Myers JK. Six month prevalence of psychiatric disorders in three communities. Arch Gen Psychiatry 1984; 41: 959–67

    PubMed  CAS  Google Scholar 

  10. Robins LN. Lifetime prevalence of specific psychiatric disorders in three states. Arch Gen Psychiatry 1984; 41: 949–58

    PubMed  CAS  Google Scholar 

  11. Zung WWK. Prevalence of clinically significant anxiety in a family practice setting. Am J Psychiatry 1986; 143: 1471–2

    PubMed  CAS  Google Scholar 

  12. Myers BS, Yesavage JA, Green M, et al. The treatment of anxiety in elderly patients. Top Psychiatry Prim Care Physician 1989; 1(1): 6

    Google Scholar 

  13. Small GW. Psychopharmacological treatment of elderly demented patients. J Clin Psychiatry 1988; 49 Suppl.: 8–13

    PubMed  Google Scholar 

  14. Hamilton M. The symptomatology of anxiety. In: Obasha A, editor. Psychopathology of anxiety and its management. Cairo: World Psychiatric Association, 1981

    Google Scholar 

  15. Baughman III OL. Anxiolytic perspectives for primary care physicians. Fam Pract Recertification 1989; 11 Suppl.: 117–25

    Google Scholar 

  16. Jenike MA. Treating anxiety in elderly patients. Geriatrics 1983; 38: 115–9

    PubMed  CAS  Google Scholar 

  17. Landry MJ, Smith DE, Steinberg JR. Anxiety, depression and substance abuse disorders: diagnosis, treatment and prescribing practices. J Psychoactive Drugs 1991; 23(4): 397–416

    PubMed  CAS  Google Scholar 

  18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-III-R). 3rd rev. ed. Washington: APA, 1987

    Google Scholar 

  19. Barbee JG, McLaulin JB. Anxiety disorders: diagnosis and pharmacotherapy in the elderly. Psychiatric Ann 1990; 20(8): 439–45

    Google Scholar 

  20. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50–5

    PubMed  CAS  Google Scholar 

  21. Osgood N. Identifying and treating the geriatric alcoholic. Geriatr Med Today 1988; 7(8): 53–6

    Google Scholar 

  22. Moos RH. Substance abuse treatment in the elderly. J Stud Alcohol 1993; 54: 479–87

    PubMed  CAS  Google Scholar 

  23. Goldberg HL. Modern treatment modalities in anxiety. S Afr Med J 1989; 75: 32–3

    Google Scholar 

  24. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993; 328(19): 1398–405

    PubMed  CAS  Google Scholar 

  25. Roth M. Differential diagnosis of psychiatric disorders in old age. Hospital Pract 1986; 21: 111–38

    CAS  Google Scholar 

  26. Nakra BRS, Grossberg GT. Management of anxiety in the elderly. Compr Ther 1986; 12(10): 53–60

    PubMed  CAS  Google Scholar 

  27. Smith GR, Monson RT, Ray DC. Patients with multiple unexplained symptoms: their characteristics, functional health and health care utilization. Arch Intern Med 1986; 146: 69–72

    PubMed  Google Scholar 

  28. Klerman GL, Weissman MM, Ouellette R, et al. Panic attacks in the community: social morbidity and health care utilization. JAMA 1991; 265: 742–6

    PubMed  CAS  Google Scholar 

  29. Croft-Jeffreys C, Wilkinson G. Estimated costs of neurologic disorder in UK general practice 1985. Psychol Med 1989; 19: 549–58

    PubMed  CAS  Google Scholar 

  30. Katon WJ, Von Korff M, Lin E. Panic disorder: relationship to high medical utilization. Am J Med 1992; 92 (1A Suppl.): 7S–11S

    PubMed  CAS  Google Scholar 

  31. Markowitz JS, Weissman MM, Ouellette R, et al. Quality of life in panic disorder. Arch Gen Psych 1989; 46: 984–92

    CAS  Google Scholar 

  32. Allgulander C, Lavori PW. Excess mortality among 3302 patients with ‘pure’ anxiety neurosis. Arch Gen Psychiatry 1991; 48: 599–602

    PubMed  CAS  Google Scholar 

  33. Bressler R. Multiple drug use in an elderly man. Hosp Pract 1987; July: 111–27

  34. Kusserow RP. Medicare drug utilization review. Washington DC: Department of Health and Human Services; 1989 Jan. Federal Register No. 54 SR 24

  35. Thompson TL, Moran GM, Nies AS, et al. Medical intelligence drug therapy: psychotropic drug use in the elderly. N Engl J Med 1983; 308: 134–8, 194–9

    PubMed  Google Scholar 

  36. Lippman S. Geriatric aspects of psychopharmacology, Pt A. J Ky Med Assoc 1987; June: 337–40

  37. Cadieux RJ, Sussman N, Turnbull JM. Using psychoactive drugs in the elderly. Patient Care 1989; 23(7): 57–94

    Google Scholar 

  38. Steinberg JR. Prescription drug impairment in the elderly. Drug Ther 1990; Aug (Suppl.): 83–100

  39. Domantay AG, Napoliello MJ. Buspirone for elderly anxious patients: a review of clinical studies. Family Practice Recertification 1989; 11 Suppl. 9: 17–23

    Google Scholar 

  40. Lader MH. National use of anxiolytic drugs. Natl Drug Ther 1987; 21: 1–5

    CAS  Google Scholar 

  41. Rosenbaum JF. Medical intelligence —current concepts in psychiatry: the drug treatment of anxiety. N Engl J Med 1982; 306: 401–4

    PubMed  CAS  Google Scholar 

  42. American Psychiatric Association. Benzodiazepine dependence, toxicity and abuse. Washington: APA, 1990

    Google Scholar 

  43. Mellinger GD, Balter MB, Uhlenhuth EH. Prevalence and correlates of the long term regular use of anxiolytics. JAMA 1984; 251: 375–9

    PubMed  CAS  Google Scholar 

  44. Cross-National Collaborative Panic Study, Second Phase Investigators. Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine and placebo. Br J Psychiatry 1992; 160: 191–202

    Google Scholar 

  45. Ballenger JC, Burrows GD, DuPont Jr RL, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial, I: efficacy in short-term treatment. Arch Gen Psychiatry 1988; 45: 413–22

    PubMed  CAS  Google Scholar 

  46. Cohn JB, Wilcox CS. Long term comparison of alprazolam and placebo in patients with an anxiety disorder. Pharmacotherapy 1984; 4: 93–8

    PubMed  CAS  Google Scholar 

  47. Murphy SM, Owen R, Tyrer P. Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks treatment with diazepam or buspirone. Br J Psychiatry 1989; 154: 529–34

    PubMed  CAS  Google Scholar 

  48. Fabre LD, McLendon DM, Stephens AG. Comparison of the therapeutic effect, tolerance and safety of ketazolam and diazepam administered for six months to out-patients with chronic anxiety neurosis. J Int Med Res 1981; 9: 191–8

    PubMed  CAS  Google Scholar 

  49. Rickels K, Schweizer E, Csanalosi I, et al. Long-term treatment of anxiety and risk of withdrawal: prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 1988; 45: 444–50

    PubMed  CAS  Google Scholar 

  50. Gambert SR, Grossberg GT, Morley JE. How many drugs does your aged patient need? Patient Care 1994; 28: 61–72

    Google Scholar 

  51. Kales A, Soldatos CR, Bixler EO, et al. Rebound insomnia and rebound anxiety: a review. Pharmacology 1983; 26(3): 121–37

    PubMed  CAS  Google Scholar 

  52. Patterson JR. Triazolam syndrome in the elderly. South Med J 1987; 80(11): 1425–6

    PubMed  CAS  Google Scholar 

  53. Bixler EO, Kales A, Manfredi RL, et al. Next-day memory impairment with triazolam use. Lancet 1991; 337: 827–31

    PubMed  CAS  Google Scholar 

  54. Rickels, K, Case WG, Diamond L. Relapse after short term drug therapy in neurotic outpatients. Int Pharmacopsychiatry 1980; 15: 186–92

    PubMed  CAS  Google Scholar 

  55. Rickels K, Case WG, Downing RW, et al. One year follow up of anxious patients treated with diazepam. J Clin Psychopharmacol 1986; 6: 32–6

    PubMed  CAS  Google Scholar 

  56. Rickels K, Case WG, Schweizer E, et al. Long term benzodiazepine users 3 years after participation in a discontinuation program. Am J Psychiatry 1991; 148: 757–61

    PubMed  CAS  Google Scholar 

  57. Busto U, Sellers EM, Naranjo CA, et al. Withdrawal reaction after long term therapeutic use of benzodiazepines. N Engl J Med 1986; 315: 854–9

    PubMed  CAS  Google Scholar 

  58. Stein MD. Changes in the pattern of drug overdoses. J Gen Intern Med 1993; 8: 179–84

    PubMed  CAS  Google Scholar 

  59. Miller NS, Belkin BM, Gold MS. Alcohol and drug dependence among the elderly: epidemiology, diagnosis, and treatment. Comprehensive Psychiatry 1991; 32(2): 153–65

    PubMed  CAS  Google Scholar 

  60. Thibault JM, Maly RC. Recognition and treatment of substance abuse in the elderly. Primary Care 1993; 20(1): 155–65

    PubMed  CAS  Google Scholar 

  61. Smith D, Wesson D. Benzodiazepine dependency syndromes. J Psychoactive Drugs 1983; 15: 85–95

    PubMed  CAS  Google Scholar 

  62. Smith DE. Benzodiazepine substance abuse potential: current studies and trends. J Subst Abuse Treat 1984; 1: 163–7

    PubMed  CAS  Google Scholar 

  63. Higgett A. Clinical Management of benzodiazepine dependence. BMJ 1985; 291: 688–90

    Google Scholar 

  64. Steinberg JR. Anxiolytic therapy and addiction: primary care concerns. Intern Med Certification 1989; 3(2): 126–34

    Google Scholar 

  65. Rummans TA. Learning and memory impairment in older, detoxified benzodiazepine dependent patients. Mayo Clin Proc 1993; 68: 731–7

    PubMed  CAS  Google Scholar 

  66. Hokkanen R, Ertama L, Linnoila M, et al. Role of drugs in traffic accidents. BMJ 1980; 281: 1309–12

    Google Scholar 

  67. Skegg DCG, Richards SM, Doll R. Minor tranquilizers and road accidents. BMJ 1979; 280: 917–9

    Google Scholar 

  68. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med 1988; 319: 1701–7

    PubMed  CAS  Google Scholar 

  69. Granek E, Baker SP, Abbey H, et al. Medications and diagnoses in relation to falls in long term care facilities. J Am Geriatr Soc 1987; 35: 503–11

    PubMed  CAS  Google Scholar 

  70. Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316: 363–9

    PubMed  CAS  Google Scholar 

  71. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989; 262(23): 3303–7

    PubMed  CAS  Google Scholar 

  72. Oster G, Russell MW, Huse DM, et al. Accident-and injuryrelated health care utilization among benzodiazepine users and non-users. J Clin Psychiatry 1987; 48 (12 Suppl.): 17–21

    PubMed  Google Scholar 

  73. Dawson-Butterworth K. The chemopsychotherapeutics of geriatric sedation. J Am Geriatr Soc 1970; 18: 97–116

    PubMed  CAS  Google Scholar 

  74. Gershon S. Antianxiety agents. Adv Behav Biol 1973; 6: 183–7

    Google Scholar 

  75. Cook PJ. Benzodiazepine hypnotics in the elderly. Acta Psychiatr Scand Suppl 1986; 74 Suppl. 332: 149–58

    Google Scholar 

  76. Baughman III OL. The safety record of buspirone in generalized anxiety disorder. J Clin Psychiatry. J Clin Psychiatry Monograph 1994; 12: 37–43

    Google Scholar 

  77. Wu Y, Rayburn JW. Psychosedative agents: 2,8-(4-substituted l-piperazinylalkyl)-8-azaspiro[4,5]decane-7,9-diones. J Med Chem 1972; 15: 477–9

    CAS  Google Scholar 

  78. Goldberg HL, Finnerty RJ. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am J Psychiatry 1979; 136: 1184–5

    PubMed  CAS  Google Scholar 

  79. Feighner JP, Meredith CH, Hendrickson GA. A double blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J Clin Psychiatry 1982; 43 (12 Suppl. sec. 2): 103–7

    PubMed  CAS  Google Scholar 

  80. Dimitriou EC, Parashos AJ, Giouzepas JS. Buspirone vs alprazolam. A double-blind comparative study of their efficacy, adverse effects and withdrawal symptoms. Drug Invest 1992; 4(4): 316–21

    Google Scholar 

  81. Robinson D, Napoliello MJ, Schenk J. The safety and usefulness of buspirone as an anxiolytic drug in elderly versus young patients. Clinical Therapeutics 1988; 10(6): 739–46

    Google Scholar 

  82. Charney DS, Woods SW, Krystal JH, et al. Serotonin function and human anxiety disorders. Ann NY Acad Sci 1990; 600: 558–73

    PubMed  CAS  Google Scholar 

  83. Taylor DP. Serotonin agents in anxiety. Ann NY Acad Sci 1990; 600: 545–57

    PubMed  CAS  Google Scholar 

  84. Glitz DA, Pohl R. 5HT1A partial agonists: what is their future? Drugs 1991; 41(1): 11–8

    PubMed  CAS  Google Scholar 

  85. Eison MS. The new generation of serotonergic anxiolytics: possible clinical roles. Psychopathology 1989; 22 (1 Suppl.): 13–20

    PubMed  Google Scholar 

  86. Eison AS, Temple Jr DL. Buspirone: review of its pharmacology and current perspectives on its mechanism of action. Am J Med 1986; 80: 1–9

    PubMed  CAS  Google Scholar 

  87. Riblet LA, Taylor DP, Eison MS, et al. Pharmacology and neurochemistry of buspirone. J Clin Psychiatry 1982; 43: 11–6

    PubMed  CAS  Google Scholar 

  88. Riblet LA, Eison AS, Eison MS, et al. Neuropharmacology of buspirone. Psychopathology 1984; 17: 69–78

    PubMed  CAS  Google Scholar 

  89. Eison AS, Eison MS, Stanley M, et al. Serotonergic mechanisms in the behavioral effects of buspirone and gepirone. Pharmacol Biochem Behav 1986; 24: 701–7

    PubMed  CAS  Google Scholar 

  90. Peroutka J. Selective interaction of novel anxiolytics with 5-hydroxytryptamine 1-A receptors. Biol Psychiatry 1985; 20: 971–9

    PubMed  CAS  Google Scholar 

  91. Cohn JB, Bowden CL, Fisher JG, et al. Double-blind comparison of buspirone and clorazepate in anxious outpatients. Am J Med 1986; 80 (3B Suppl.): 10–6

    PubMed  CAS  Google Scholar 

  92. Gammans R. The metabolism and disposition of buspirone. Am J Med; 80 (3B Suppl.): 41–51

  93. Gershon S. Drug interactions in controlled clinical trials. J Clin Psychiatry 1982; 12(2): 95–8

    Google Scholar 

  94. Gammans RE. The effects of buspirone binding on the binding of digoxin, dilantin, propanolol and warfarin to human plasma. Fed Proc 1985; 44: 1123

    Google Scholar 

  95. Molitor J. Effect of buspirone on mixed function oxidase activity in rats. Fed Proc 1985; 44: 1257

    Google Scholar 

  96. Mattila MJ, Aranko K, Seppala T. Acute effects of buspirone and alcohol on psychomotor skills. J Clin Psychiatry 1982; 43(12): 56–60

    PubMed  CAS  Google Scholar 

  97. Moskowitz H, Smiley A. Effects of chronically administered buspirone and diazepam on driving-related skills performance. J Clin Psychiatry 1982; 43(12): 45–55

    PubMed  CAS  Google Scholar 

  98. Jann MW, Froemming JH, Borison RL. Movement disorders and new azapirone anxiolytic drugs. J Am Board Fam Pract 1990; 3(2): 111–9

    PubMed  CAS  Google Scholar 

  99. Lader M. Psychosocial effects of buspirone. J Clin Psychiatry 1982; 43 (12 sec. 2): 62–7

    PubMed  CAS  Google Scholar 

  100. Rickels K, Weisman K, Norstad N, et al. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 1982; 43 (12 Suppl. sec. 2): 81–6

    PubMed  CAS  Google Scholar 

  101. Goldberg HL, Finnerty RJ. Comparison of buspirone in two separate studies. J Clin Psychiatry 1982; 43 (12 sec. 2): 87–91

    PubMed  CAS  Google Scholar 

  102. Man GCW, Hsu K, Sproule BJ. Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest 1986; 90(6): 832–6

    PubMed  CAS  Google Scholar 

  103. Sullivan RJ. Respiratory depression requiring ventilatory support following 0.5 mg of triazolam. J Am Geriatr Soc 1989; 37(5): 450–2

    PubMed  Google Scholar 

  104. Rapoport DM, Greenberg HE, Goldring RM. Comparison of the effects of buspirone and diazepam on control of breathing. FASEB J 1988; 2: A1507

    Google Scholar 

  105. Rapoport DM, Mendelson WH. Buspirone —a new respiratory stimulant. Am Rev Respir Dis 1989; 139: 940–5

    Google Scholar 

  106. Garner SJ, Eldridge FL, Wagner PJ, et al. Buspirone, an anxiolytic drug that stimulates respiration. Am Rev Respir Dis 1989; 139: 946–50

    PubMed  CAS  Google Scholar 

  107. Cole JO, Orzack MH, Beake B, et al. Assessment of the abuse liability of buspirone in recreational sedative users. J Clin Psychiatry 1982; 43 (12 Suppl. sec. 2): 69–74

    PubMed  CAS  Google Scholar 

  108. Griffith JD, Jasinski DR, Casten GP. Investigation of the abuse liability of buspirone in alcohol-dependent patients. Am J Med 1986; 80 (3B Suppl.): 30–5

    PubMed  CAS  Google Scholar 

  109. Lader M. Assessing the potential for buspirone dependence or abuse and effects of its withdrawal. Am J Med 1987; 82: 20–6

    PubMed  CAS  Google Scholar 

  110. Rakel RE. Long-term buspirone therapy for chronic anxiety: a multicenter international study to determine safety. South Med J 1990; 83: 194–8

    PubMed  CAS  Google Scholar 

  111. Rickeis K, Schweizer E. The clinical course and long-term management of generalized anxiety disorder. J Clin Psychopharmacol 1990; 10 (3 Suppl.): 101S–110S

    Google Scholar 

  112. Feighner JP. Buspirone in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 1987; 48 (12 Suppl.): 3–6

    PubMed  Google Scholar 

  113. Gammans RE, Westrick ML, Shea JP, et al. Pharmacokinetics of buspirone in elderly subjects. J Clin Pharmacol 1989; 29: 72–8

    PubMed  CAS  Google Scholar 

  114. Robinson D, Napoliello MJ, Schenck J. The safety and usefulness of buspirone as an anxiolytic drug in elderly versus young patients. Clin Ther 1988; 10: 740–6

    PubMed  CAS  Google Scholar 

  115. Napoliello MJ. An interim multicentre report on 677 anxious geriatric out-patients treated with buspirone. Br J Clin Pract 1986; 40(2): 71–3

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine, University of Maryland, Maryland, USA

    John R. Steinberg

Authors
  1. John R. Steinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steinberg, J.R. Anxiety in Elderly Patients. Drugs & Aging 5, 335–345 (1994). https://doi.org/10.2165/00002512-199405050-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199405050-00003

Keywords

Search

Navigation